Source-grounded facts extracted from BioAge Labs, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
BioAge Labs, Inc. shareholders approved Ratification of the appointment of KPMG LLP as the independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-10 meeting.
“2. The ratification of the appointment of KPMG LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026. The vote tally was as follows: Shares For Shares Against Shares Abstaining 36,561,171 1,305 25,128”
BioAge Labs, Inc. shareholders approved Election of three Class II Directors, Patrick Enright, James I. Healy, and Rekha Hemrajani, each to serve a three-year term at the 2026-06-10 meeting.
“1. The election of three Class II Directors, Patrick Enright, M.B.A., James I. Healy, M.D., Ph.D., and Rekha Hemrajani, M.B.A., each to serve a three-year term, which will expire at the 2029 Annual Meeting of Stockholders and until such time as their respective successors have been duly elected and qualified or until such director’s earlier resignation or removal. The vote tally was as follows: Nominees Shares For Shares Withheld Broker Non-Votes Patrick Enright, M.B.A. 30,075,928 1,184,271 5,327,405 James I. Healy, M.D., Ph.D. 25,499,205 5,760,994 5,327,405 Rekha Hemrajani, M.B.A. 27,826,781 3,433,418 5,327,405”
BioAge Labs, Inc. reported first quarter ended March 31, 2026 results: revenue 2.8 million, net income -22.3 million, EPS -0.52.
“with Lilly ExploR&D for the development of therapeutic antibodies targeting novel metabolic aging targets. First Quarter 2026 Financial Results Collaboration revenue was $2.8 million for the quarter ended March 31, 2026, compared to $1.5 million for the same period in 2025. The $1.3 million increase in collaboration revenue was due to increased full-time”
BioAge Labs, Inc. entered into Underwriting Agreement with Goldman Sachs & Co. LLC, Piper Sandler & Co. and Citigroup Global Markets Inc. as representatives of the underwriters valued at $107.6 million (effective 2026-01-21).
“On January 21, 2026, BioAge Labs, Inc., a Delaware corporation (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Goldman Sachs & Co. LLC, Piper Sandler & Co. and Citigroup Global Markets Inc. as representatives of the underwriters named therein (the “ Underwriters ”), pursuant to which the Company agreed to issue and sell 5,897,435 shares (the “ Underwritten Shares ”) of its common stock, par value $0.00001 per share (“ Common Stock ”) to the Underwriters in a public offering at a price of $19.50 per Underwritten Share (the “ Offering ”).”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.